Summit Global Investments boosted its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Free Report) by 26.4% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 37,300 shares of the company’s stock after purchasing an additional 7,800 shares during the period. Summit Global Investments owned about 0.08% of Amphastar Pharmaceuticals worth $1,399,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Royce & Associates LP purchased a new position in Amphastar Pharmaceuticals during the first quarter valued at approximately $837,000. Los Angeles Capital Management LLC lifted its stake in Amphastar Pharmaceuticals by 164.8% in the first quarter. Los Angeles Capital Management LLC now owns 26,475 shares of the company’s stock valued at $993,000 after acquiring an additional 16,475 shares during the last quarter. Granite Investment Partners LLC acquired a new stake in Amphastar Pharmaceuticals in the first quarter valued at approximately $20,131,000. LSV Asset Management lifted its stake in Amphastar Pharmaceuticals by 210.3% in the first quarter. LSV Asset Management now owns 33,200 shares of the company’s stock valued at $1,245,000 after acquiring an additional 22,500 shares during the last quarter. Finally, Jackson Creek Investment Advisors LLC acquired a new stake in Amphastar Pharmaceuticals in the first quarter valued at approximately $970,000. 62.49% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling at Amphastar Pharmaceuticals
In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 10,500 shares of the firm’s stock in a transaction on Thursday, May 18th. The stock was sold at an average price of $44.35, for a total transaction of $465,675.00. Following the transaction, the chief financial officer now directly owns 105,148 shares in the company, valued at approximately $4,663,313.80. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 10,500 shares of the firm’s stock in a transaction on Thursday, May 18th. The stock was sold at an average price of $44.35, for a total transaction of $465,675.00. Following the transaction, the chief financial officer now directly owns 105,148 shares in the company, valued at approximately $4,663,313.80. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO William J. Peters sold 11,000 shares of the firm’s stock in a transaction on Friday, June 2nd. The shares were sold at an average price of $46.35, for a total value of $509,850.00. Following the sale, the chief financial officer now directly owns 105,603 shares of the company’s stock, valued at $4,894,699.05. The disclosure for this sale can be found here. In the last three months, insiders have sold 112,547 shares of company stock worth $5,285,601. Corporate insiders own 27.80% of the company’s stock.
Analyst Upgrades and Downgrades
Several research firms have recently weighed in on AMPH. StockNews.com raised shares of Amphastar Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, June 21st. Jefferies Financial Group initiated coverage on shares of Amphastar Pharmaceuticals in a research note on Tuesday, July 25th. They issued a “buy” rating and a $70.00 price target on the stock. Finally, Piper Sandler boosted their target price on shares of Amphastar Pharmaceuticals from $55.00 to $66.00 in a report on Tuesday, July 18th.
Amphastar Pharmaceuticals Stock Performance
NASDAQ:AMPH opened at $60.59 on Wednesday. The company has a market capitalization of $2.92 billion, a PE ratio of 33.88 and a beta of 0.82. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $26.76 and a fifty-two week high of $63.72. The company has a 50 day simple moving average of $53.55 and a two-hundred day simple moving average of $42.18. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.88 and a current ratio of 3.86.
Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Free Report) last posted its quarterly earnings results on Tuesday, May 9th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.40 by $0.12. Amphastar Pharmaceuticals had a return on equity of 18.37% and a net margin of 17.96%. The firm had revenue of $140.02 million for the quarter, compared to analysts’ expectations of $130.50 million. Research analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 2.46 earnings per share for the current year.
Amphastar Pharmaceuticals Company Profile
(Free Report)
Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API).
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Amphastar Pharmaceuticals, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Amphastar Pharmaceuticals wasn’t on the list.
While Amphastar Pharmaceuticals currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today’s challenging market? Click the link below and we’ll send you MarketBeat’s list of ten stocks that will drive in any economic environment.
Get This Free Report